Regulatory Amgen’s BiTE for lung cancer backed for EU approval PharmaphorumAmgen's fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 30, 2026) Pharmaphorum Amgen’s fast-growing bispecific T-cell engager Imdylltra should be cleared as a second-line therapy for small cell lung cancer, said the CHMP. RegulatoryOncologyRead full story Post navigation Previous: Trustworthy AI in clinical oversightNext: The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026